Katie Kelley
| Name | |
| Katie Kelley | |
| katie.kelley@ucsf.edu | |
| Organization | |
| UCSF | |
| Can you tell us a bit about yourself? | |
| I am a GI Medical Oncologist at UCSF and lead our hepatobiliary cancer clinical research program. | |
| Can you share one or two of your specific research interests? | |
| Developing new targeted therapies and immunotherapies for biliary tract cancers and hepatocellular carcinoma. Identifying molecular and clinical factors associated with risk and response in hepatobiliary cancers. |
|
| Why did you decide to specialize in hepatobiliary cancers? | |
| I wanted to contribute my efforts to a complex family of cancers -- and the patients with those cancers -- with enormous unmet need in oncology. | |
| Can you describe one of the unforgettable moments in your patients care or research that has impacted your career? | |
| Seeing some of my cholangiocarcinoma patients achieve complete and prolonged responses to immunotherapy has been among the most unforgettable, impactful, and meaningful moments in my career and has led to my goal of finding new combinations to improve patients' chances of experiencing an immune response. | |
| Can you tell us one thing collaboration with colleagues could accomplish that you could not accomplish on your own? | |
| Collaboration is essential in cancer research, especially in rare cancers with even rarer molecular subgroups. Completing clinical trials of targeted therapies such as FGFR2 inhibitors or IDH1 inhibitors would not be possible without large collaborations, and these collaborations enrich all of our understanding of the disease. | |
| How did you learn about the Cholangiocarcinoma Foundation? | |
| Stacie sent me an email long ago to introduce me to collaborators across the country -- a collaboration which is ongoing to this day! | |